Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients

Clinical Pharmacokinetics

Volumn 44, Issue 6, 2005, Pages 627-635

  Navarro, Amparo Sánchez ^a   Gandarillas, Clara Isabel Colino ^a   Lerma, Francisco Alvarez ^b   Menacho, Y Alcalde ^b   Domínguez Gil, Alfonso ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASSISTED VENTILATION; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DEMOGRAPHY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; EVALUATION; HUMAN; INTENSIVE CARE; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE REGRESSION; PLASMA CLEARANCE; PRIORITY JOURNAL; PROBABILITY; RESPIRATORY TRACT INFECTION; STATISTICAL SIGNIFICANCE; STEADY STATE;

AGED; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPUTER SIMULATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE; MALE; MIDDLE AGED; MONTE CARLO METHOD; OFLOXACIN; PROSPECTIVE STUDIES; REGRESSION ANALYSIS;

EID: 22244464898     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200544060-00004     Document Type: Article

References (37)

1. Eliopoulos GM, Wennersten CB, Moellering Jr RC. Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria. Diagn Microbiol Infect Dis 1996; 25: 35-41
2. Fujimoto T, Mitsuhashi S. In vitro antibacterial activity of DR-3355, the S-(-)isomer of ofloxacin. Chemotherapy 1990; 36: 268-76
3. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc., 1982
4. Baltch AL, Smith RP, Ritz W. Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin and rifampin used singly and in combination against Legionella pneumophila. Antimicrob Agents Chemother 1995; 39: 1661-6
5. Hammerschlag MR, Wumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, levofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992; 36: 1573-4
6. Molitoris E, Wexler HM, Finegold SM. In vitro activity of levofloxacin against bacteria from skin and soft tissue infec-tions [abstract no. E88]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15-18; New Orleans
7. Centers for Disease Control and Prevention. Tuberculosis morbidity: United States, 1997. MMWR Morb Mortal Wkly Rep 1998; 47: 253-7
8. Chien SC, Rogge MC, Gisclon LG, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral and intravenous doses. Antimicrob Agents Chemother 1997; 41: 2256-60
9. Holland ML, Chien S-C, Corrado ML, et al. The pharmacokinetic profile of levofloxacin following once or twice daily 500mg oral administration of levofloxacin hemihydrate [abstract]. 5th International Symposium on New Quinolones; 1994 Aug 25-27; Singapore
10. Nakashima M, Uematsu T, Kanamaru M, et al. Phase I study of levofloxacin, (S)-(-) ofloxacin. Jpn J Clin Pharmacol Ther 1992; 23: 515-20
11. Tanigawara Y, Nomura H, Kagimoto N, et al. Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. Biol Pharm Bull 1995; 18: 315-20
12. Aoki N, Usuda Y, Koda Y, et al. Clinical pharmacology and efficacy of levofloxacin in elderly patients. Jpn J Antibiot 1992; 45: 530-8
13. Gisclon LG, Curtin CR, Williams RR, et al. The pharmacokinet-ics of levofloxacin in subjects with renal impairment, and in subjects receiving hemodialysis or continuous ambulatory peritoneal dialysis [abstract no. A13]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15-18; New Orleans
14. Saito A, Oguchi K, Harada Y, et al. Pharmacokinetics of levofloxacin in patients with impaired renal function. Chemotherapy 1992; 45: 530-8
15. Chien SC, Chow AT, Rogge MC, et al. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine. Antimicrob Agents Chemother 1997; 41: 1765-9
16. Goodwin SD, Gallis HA, Chow AT, et al. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1994; 38: 799-804
17. Piscitelli SC, Spooner K, Baird B, et al. Pharmacokinetics and safety of high-dose and extended interval regimens of levofloxacin in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1999; 43: 2323-7
18. Shentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles: I. Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxine, ciprofloxacin and tobramycin. DICP 1991; 25: 1050-7
19. Peloquin CA, Cumbo T, Nix DE, et al. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections: impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch Intern Med 1989; 149: 2269-73
20. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory infections. J Chemother 1997; 9 Suppl. 3: 38-44
21. Drusano GL. Fluoroquinolones pharmacodynamics: prospective determination of relationships between exposure and outcome. J Chemother 2000; 12 Suppl. 4: 21-6
22. Drusano GL, Preston SL, Owens RC, et al. Fluoroquinolone pharmacodynamics. Clin Infect Dis 2001; 33: 2091-6
23. Wright DH, Brown GH, Peterson ML, et al. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000; 46: 669-83
24. Insausti J. Consumo de antibióticos en Medicina Intensiva. In: Alvarez-Lerma F, editor. Estudio Nacional de Vigilancia de Infección Nosocomial en UCI (ENVIN-UCI). Madrid: Jarpyo editories (SA), 2002: 129-48
25. Boroujerdi M. Pharmacokinetics: principles and applications. New York: McGraw-Hill, 2001
26. Le Gall JR, Lemeshow S, Saulvier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270: 2657-63
27. Bauer LA. Applied clinical pharmacokinetics. New York: McGraw-Hill, 2001
28. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
29. Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 1988; 84: 1053-60
30. Martínez Martínez MS, Gutiérrez Hurtado B, Colino Gandarillas CI, et al. In vitro study of experimental factors affecting the microdialysis results. Anal Chim Acta 2002; 459: 143-50
31. Bonate PL. A brief introduction to Monte Carlo simulation. Clin Pharmacokinet 2001; 40: 15-22
32. Nicolau DP, Ambrose P. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoni-ae. Am J Med 2001; 111: 13-18S
33. Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis 1997; 25: 112-8
34. van-Dalen R, Vree TB. Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med 1990; 16: S235-8
35. Romano S, Fenández de Gatta MM, Calvo MV, et al. Influence of clinical diagrams in the population pharmacokinetics of amikacin in intensive care unit patients. Clin Drug Invest 1998; 15: 435-44
36. Lister PD. Pharmacodynamics of 750mg and 500mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2002; 44: 43-9
37. Rodvold KA, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 2001; 21: 233-52S